Revolutions Medical Corporation Dramatically Streamlines Flagship Product, Readies for Mass Production and Commercial Launch

MOUNT PLEASANT, SC--(Marketwire - September 09, 2009) - Revolutions Medical Corporation (“Revolutions Medical” or the “Company”) (OTCBB: RMCP), producers of the Rev Vac safety syringe, today announced that it has completed a significant redesign of its flagship Rev Vac syringe, reducing the product’s part count by nearly 30% and clearing the remaining economic hurdles to mass production and commercial launch. The Rev Vac safety syringe is already FDA approved.

“In this simple but bold redesign we not only made the final strides toward a market-ready product but have ensured a cost benchmark that will be difficult to compete with as well,” stated Revolutions Medical CEO Ron Wheet. “By reducing the Rev Vac’s part count we have accomplished two vital goals: 1) fewer parts simplifies the manufacturing process, slicing our upfront capital required and 2) the Rev Vac syringe performs even better than it did previously, and we have further reduced the variability of this already dependable product. This redesign places the Rev Vac safety syringe in a highly desirable competitive position, and the benefits of this design improvement will extend to our entire product line of safety syringes.

“This final milestone puts us firmly on pace to achieve our intended Q4 ’09 mass market launch.”

To be added to the Revolutions Medical investor email list, please email justin.davis@cirrusfc.com with RMCP in the subject line.

About Revolutions Medical Corporation (www.revolutionsmedical.com)

Revolution Medical’s products include the Rev Vac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. Revolutions Medical also provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D and automatic segmentation of images.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.